When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOV - Myovant's relugolix successful in late-stage uterine fibroid study; shares up 2% premarket
Myovant Sciences Ltd.
Myovant Sciences (NYSE:MYOV) perks up 2% premarket on light volume on the heels of a positive outcome from a Phase 3 clinical trial, LIBERTY 1, evaluating relugolix, co-administered with low-dose estradiol and norethindrone, in women with uterine fibroids with heavy menstrual bleeding.
More news on: Myovant Sciences Ltd., Healthcare stocks news, Stocks on the move,